DexCom, Inc. $DXCM Stock: Kornitzer Capital Management Inc. KS Lowers Position

Posted by Brenda Bartman on Nov 9th, 2026

Kornitzer Capital Management Inc. KS lowered its holdings in DexCom, Inc. (NASDAQ:DXCM – Free Report) by 17.4% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 48,937 shares of the medical device company’s stock after selling 10,319 shares during the period. Kornitzer Capital Management Inc. KS’s holdings in DexCom were worth $4,223,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Mather Group LLC. boosted its holdings in shares of DexCom by 27.7% in the 3rd quarter. Mather Group LLC. now owns 563 shares of the medical device company’s stock worth $49,000 after purchasing an additional 122 shares in the last quarter. Fifth Third Wealth Advisors LLC boosted its position in DexCom by 2.8% during the 3rd quarter. Fifth Third Wealth Advisors LLC now owns 5,510 shares of the medical device company’s stock valued at $475,000 after buying an additional 150 shares during the period. Elevation Wealth Partners LLC grew its holdings in DexCom by 61.0% in the 3rd quarter. Elevation Wealth Partners LLC now owns 401 shares of the medical device company’s stock worth $35,000 after acquiring an additional 152 shares during the last quarter. MassMutual Private Wealth & Trust FSB grew its holdings in DexCom by 15.4% in the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 1,147 shares of the medical device company’s stock worth $77,000 after acquiring an additional 153 shares during the last quarter. Finally, Simplicity Wealth LLC grew its holdings in DexCom by 5.4% in the 3rd quarter. Simplicity Wealth LLC now owns 3,169 shares of the medical device company’s stock worth $273,000 after acquiring an additional 162 shares during the last quarter. 97.75% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, EVP Jereme Sylvain sold 3,638 shares of the firm’s stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $83.27, for a total transaction of $302,936.26. Following the sale, the executive vice president owned 146,828 shares of the company’s stock, valued at $12,226,367.56. This trade represents a 2.42% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Nicholas Augustinos sold 6,539 shares of DexCom stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $84.04, for a total transaction of $549,537.56. Following the completion of the sale, the director owned 29,293 shares of the company’s stock, valued at $2,461,783.72. This represents a 18.25% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 22,822 shares of company stock valued at $1,920,193. Insiders own 0.28% of the company’s stock.

DexCom Price Performance

Shares of NASDAQ DXCM opened at $79.41 on Monday. The company has a 50 day simple moving average of $85.21 and a two-hundred day simple moving average of $75.01. The company has a market capitalization of $29.62 billion, a price-to-earnings ratio of 31.14, a P/E/G ratio of 1.31 and a beta of 1.45. DexCom, Inc. has a fifty-two week low of $54.11 and a fifty-two week high of $92.59. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.40 and a current ratio of 1.74.

DexCom (NASDAQ:DXCM – Get Free Report) last released its earnings results on Thursday, October 29th. The medical device company reported $0.73 EPS for the quarter, topping the consensus estimate of $0.68 by $0.05. The business had revenue of $1.34 billion for the quarter, compared to the consensus estimate of $1.33 billion. DexCom had a return on equity of 37.77% and a net margin of 19.42%. The company’s revenue for the quarter was up 11.1% compared to the same quarter last year. During the same period in the previous year, the company posted $0.61 earnings per share. Analysts expect that DexCom, Inc. will post 2.68 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. Piper Sandler reissued an “overweight” rating and issued a $95.00 target price (up from $88.00) on shares of DexCom in a research note on Friday, July 31st. Weiss Ratings raised DexCom from a “hold (c)” rating to a “hold (c+)” rating in a research report on Tuesday, October 6th. BTIG Research increased their price objective on DexCom from $90.00 to $96.00 and gave the stock a “buy” rating in a report on Monday, October 12th. Leerink Partners cut their price objective on DexCom from $94.00 to $87.00 and set an “outperform” rating on the stock in a research report on Monday, October 26th. Finally, Robert W. Baird set a $105.00 target price on DexCom and gave the company an “outperform” rating in a research note on Friday, July 31st. Two analysts have rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $95.50.

Check Out Our Latest Report on DXCM

DexCom Company Profile

(Free Report)

DexCom, Inc develops and markets continuous glucose monitoring (CGM) systems for people with diabetes. Its wearable sensors measure glucose levels throughout the day and send readings to compatible receivers or mobile devices, helping users monitor glucose trends and support treatment decisions.

The company’s products include its Dexcom G6 and G7 CGM systems, along with software and connected services for users and caregivers. DexCom also offers Stelo, an over-the-counter glucose biosensor designed for adults who do not use insulin.